114.95
+0.89%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About BillionToOne
From its filings with the US Securities and Exchange Commission
BillionToOne is based in Menlo Park, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker BLLN. The SEC classifies its business as medical laboratories. In the fiscal year to 31 December 2025, it reported revenue of $305.1m and net income of $7.5m. At that date it held total assets of $632.7m and shareholders' equity of $480.1m.
BillionToOne is transforming healthcare by redefining molecular diagnostics. Our revolutionary single molecule next-generation sequencing (smNGS) platform achieves what was once thought impossible—detecting and precisely quantifying genetic targets with single-molecule sensitivity. At the heart of this technological breakthrough lies our patented Quantitative Counting Templates (QCTs), enabling measurements at the physical limit of detection—the single DNA molecule. This leap forward addresses a fundamental limitation in healthcare—the inability to detect sparse but clinically crucial disease signals in cell-free DNA (cfDNA).
Our superior technology platform has enabled us to build category-defining prenatal and oncology products. Our products reveal actionable insights from a simple blood draw that are fundamentally changing how diseases are diagnosed and treated, leading to a paradigm shift in personalized medicine, overcoming the technical noise that restrains the traditional next-generation sequencing (NGS) testing methods used by other diagnostic companies. We believe our novel smNGS platform technologies combined with our AI-enhanced integrated workflow, allows us to push the technology frontier forward and deliver on the full promise of non-invasive liquid biopsy.
Quoted from its 10-K, filed 11 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Health Care Providers & Services
- Listed since
- 6 Nov 2025
- Website
- billiontoone.com ↗
- Head office
- 1035 O'BRIEN DRIVE, MENLO PARK, CA
- Incorporated in
- DE
- Classification
- Services-Medical Laboratories
- Filer status
- Non-accelerated filer<br>Emerging growth company
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- BillionToOne Inc operates in the Health Care sector with a focus on precision diagnostics.
- The company has developed a unique QCT molecular counter platform capable of counting DNA molecules at the single-count level.
- UNITY, their noninvasive prenatal screening product, detects genetic diseases using maternal blood samples.
Weaknesses
- The company is a new entrant with an IPO scheduled for 2025-11-06.
- The firm's product offerings are limited to specific genetic disease screenings.
- The company's technology is described as the only platform capable of single-count DNA molecule detection.
Opportunities
- The growing demand for noninvasive prenatal testing could expand the company's market reach.
- The unique QCT platform may attract partnerships with healthcare providers and research institutions.
- The Health Care sector's expansion presents potential for new product development and market entry.
Threats
- The company faces competition from established players in the genetic testing market.
- Regulatory changes in the Health Care sector could impact product approvals and market access.
- The IPO date is in the future, creating uncertainty around market entry and financial stability.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.